TB activists call for the disease to be made a political priority in the country and demand multisectoral departmental accountability.

Many TB medicines and formulations accessible in lower- and middle-income countries remain unaffordable or unavailable in Europe.

WHO publishes the report of the second meeting of PADO-TB2 group providing an updated list of priorities for paediatric formulations of TB medicines.

Mike Frick, TAG TB Project Co-Director, delivered comments as a civil society representative at the WHO Director-General’s TB Vaccine Accelerator Council meeting in Geneva, Switzerland. 

First-ever International leadership summit of medical associations on achieving UN High-Level Meeting targets to end TB concludes with the Kochi Declaration.

Its goal is to ensure the continued worldwide standardization of TB surveillance, in the context of WHO’s End TB Strategy, the latest WHO guidelines on TB screening, prevention, diagnosis and treatment, and commitments made at the 2023 UN High-Level Meeting on TB.

A Stop TB Partnership-led delegation of TB survivors, researchers, communities and civil society representatives attended the Multi-stakeholder Hearing on AMR to push for the inclusion of TB in the upcoming AMR Political Declaration.

The guidance includes approaches to expanding the coverage, quality and impact of existing social protection programs to people affected by TB.

WHO releases consolidated guidelines on HIV-associated TB providing a single comprehensive source for the latest evidence-informed TB/HIV recommendations.

The new 2024 update of An Activist’s Guide to Rifapentine TB Preventive Treatment: 3HP and 1HP lays out what TB community advocates need to know about rifapentine-based TB preventive treatment.